BTK and autoimmune disease: Combining these therapies with B cell-modulating agents, such as anti-CD20 antibodies or Bruton tyrosine kinase (BTK) inhibitors, may represent the next step in the evolution of these treatments, conferring multimodal activity for complex autoimmune diseases.